

DIABETES AND DIABETES-RELATED COMPLICATIONS

Our greatest interests lie in the following areas:

Insulins and Glucagon:

- Next-generation insulins (basal, ultra-rapid, high-concentration, thermostable)
- Glucose-responsive/sensing insulin
- Soluble glucagon

Incretins:

- Novel GLP-1 and dual-acting GLP-1 mimetics and novel combinations with potential for CV benefits

Technology/Devices/Formulations:

- Novel approaches relevant to the development of an artificial pancreas
- Oral peptide/protein delivery platforms and therapeutics
- Breakthrough diabetes device technology

Diabetes Complications and Novel Disease Modifiers:

Diabetes regression and durability of response

- Pathways and mechanisms that impact breakthrough weight loss (e.g., >10%) and insulin sensitization

Diabetic kidney disease

- Pathways and mechanisms related to inflammation, endothelial dysfunction (hemodynamic), remodeling and alteration of tissue metabolism

NAFLD/NASH

- Intersecting pathways of lipid metabolism, insulin sensitization and weight loss





CV: Diabetic dyslipidemia with MACE benefits

- Agents that have beneficial effects on multiple lipid/vascular risk factors such as triglycerides, LDL-C and Lp(a)

CV: Heart failure

- HFrEF and HFpEF; novel mechanisms that can be used in conjunction with the existing standard of care. Areas of focus include targets that impinge on cardiac substrate utilization and metabolism, remodeling and vascular health

Novel platforms:

- RNAi, translational modulators, cell-based therapy (e.g., for T1DM, heart failure) and microbiome modulators

Other areas:

- Type 1 Diabetes
- Endocrine disorders (e.g., growth disorders and major unmet medical needs)
- Neuropathic pain (intersects with our Pain TA)
- Novel mechanisms: Especially in the private sector, new/emerging companies and/or mechanisms that are not addressed above
- Differentiation is key. Highest priority is given to validated 'Glucose-Plus' agents (i.e., drugs that reduce HbA1c and elicit >10% weight loss and/or improvements in other CV risk factors); essentially therapeutics that can mimic bariatric surgery-like effects

Out of scope:

- Insulin secretagogues with no added metabolic benefits
- Wound healing
- Gastroparesis
- Anticoagulants
- Acute myocardial infarction/ischemia-reperfusion therapies
- Acute/ischemic stroke
- Arrhythmia
- Peripheral arterial disease

HAVE AN IDEA?

COLLABORATE WITH US.

► lilly.com/partners